At the last check on Friday, Pieris Pharmaceuticals Inc.’s (NASDAQ:PIRS) stock traded at $0.34. The average number of shares traded per day over the past five days has been 2,615,159 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0111 gain in that time frame. In the last twenty days, the average volume was 4,180,285, while in the previous 50 days, it was 4,048,672.
Since last month, PIRS stock rose 50.33%. Shares of the company fell to $0.2050 on 08/02/23, the lowest level in the past month. A 52-week high of $1.97 was reached on 02/02/23 after having rallying from a 52-week low of $0.16. Since the beginning of this year, PIRS’s stock price has dropped by -67.14% or -$0.6999, and marked a new high 12 times. However, the stock has declined by -82.65% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
PIRS stock investors should be aware that Pieris Pharmaceuticals Inc. (PIRS) stock had its last reported insider trading activity 99 days ago on May 25. KIRITSY CHRISTOPHER P, the Director of the company, purchased of 10,000 shares for $0.85 on May 25. It resulted in a $8,500 investment by the insider.
Valuation Metrics
The stock’s beta is 0.75. Besides these, the trailing price-to-sales (P/S) ratio of 1.33, the price-to-book (PB) ratio of 0.74.
Financial Health
In the three months ended June 29, Pieris Pharmaceuticals Inc.’s quick ratio stood at 1.90, while its current ratio was 1.90, showing that the company is able to pay off its debt. In the year ended June 29, EBITDA margin amounted to -157.11%, whereas operating margins totaled -86.30%. Based on annual data, PIRS earned $69.38 million in gross profit and brought in $25.9 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PIRS’s revenue rose 81.56% to $1.94 million during the quarter, while net income inched up to $20.06 million. While analysts expected Pieris Pharmaceuticals Inc. to report -$0.16 quarterly earnings, the actual figure was $0.05 per share, beating the consensus estimate by 131.20%. During the quarter, the company generated $2.82 million in EBITDA. The liabilities of Pieris Pharmaceuticals Inc. were 47.05 million at the end of its most recent quarter ended June 29, and its total debt was $12.83 million. The value of shareholders’ equity is $98.85 million.
Technical Picture
This quick technical analysis looks at Pieris Pharmaceuticals Inc.’s (PIRS) price momentum. With a historical volatility rate of 194.62%, the RSI 9-day stood at 55.58% on 31 August.
With respect to its five-day moving average, the current Pieris Pharmaceuticals Inc. price is up by +3.37% percent or $0.0111. At present, PIRS shares trade +44.72% above its 20-day simple moving average and -55.28% percent below its 100-day simple moving average. However, the stock is currently trading approximately +54.24% above its SMA50 and -65.91% below its SMA200.
Stochastic coefficient K was 39.09% and Stochastic coefficient D was 41.76%, while ATR was 0.0565. Given the Stochastic reading of 37.67% for the 14-day period, the RSI (14) reading has been calculated as 55.53%. As of today, the MACD Oscillator reading stands at -0.0258.
Analyst Ratings
Robert W. Baird upgraded its rating on Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) to an Outperform in a note to investors on March 13, 2020. The analysts firm previously had a Neutral rating on the stock.Pieris Pharmaceuticals Inc. (PIRS) has been rated Overweight by analysts. According to 0 brokerage firms, PIRS is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pieris Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $7.00, the current consensus forecast for the stock is $7.00 – $7.00. Based on these forecasts, analysts predict Pieris Pharmaceuticals Inc. (PIRS) will achieve an average price target of $7.00.
